### 1. Associated Genes
While the METAP2 gene may not directly interact with numerous genes, it can be related indirectly through pathways and processes involving translation initiation, cancer pathways, and metabolic regulation. Some genes of potential association include:
- **EIF2S1 (Eukaryotic Translation Initiation Factor 2 Subunit Alpha)**: This gene encodes a subunit of the eukaryotic initiation factor 2, which is modulated by METAP2.
- **PTEN (Phosphatase and Tensin Homolog)**: Alterations in METAP2 expression may affect PTEN function and related signaling pathways, especially in cancer contexts.
- **MTOR (Mechanistic Target of Rapamycin)**: Increased METAP2 activity may influence MTOR signaling, which is linked to cellular growth and metabolism.
- **SIRT1 (Sirtuin 1)**: This gene is implicated in aging and metabolic regulation, and its activity could be regulated in systems where METAP2 is involved.

### 2. Aging and Age-Related Diseases
Research indicates that METAP2 may play a role in cellular aging and senescence, particularly through its impact on protein synthesis and degradation pathways. Some details related to aging or age-related diseases include:
- **Neurodegenerative Diseases**: Changes in the expression of METAP2 have been suggested to affect neurodegeneration processes, although direct causal links may require further investigation.
- **Cancer**: As increased METAP2 expression is associated with various cancers, understanding its regulation may elucidate mechanisms of tumorigenesis that are often linked to aging factors.
- **Metabolism**: Its role in obesity treatment indicates potential associations with metabolic syndromes that often exacerbate with age.

### 3. Drug Interactions
Known drugs and drug classes that interact with the METAP2 gene include:
- **Fumagillin**: An antibiotic derived from fungus, known to irreversibly inhibit METAP2 activity, which has implications for oncology and possibly obesity treatment.
- **Ovalicin**: Another natural product that acts as a potent inhibitor of METAP2.
- **Anti-cancer drugs**: Investigational agents targeting METAP2 directly or its pathway components are being explored in the context of cancer therapies, but further specific drug names may depend on ongoing research.
- **Weight loss agents**: Compounds that influence methionyl aminopeptidase activity may also contribute to obesity management.

### 4. Pathways and Biological Processes
METAP2 is involved in several key biological processes, including:
- **Protein Translation**: Specifically in the cotranslational cleavage of the N-terminal methionine from nascent polypeptides.
- **Cellular Response to Stress**: By modulating the activity of eIF2, METAP2 indirectly influences mRNA translation during stress episodes, linking it to stress response pathways.
- **Signal Transduction**: As a regulator of initiation factors, it is a player in various signaling pathways that influence cell growth and metabolism.
- **Cancer-related pathways**: METAP2 affects pathways related to oncogenesis, including those governed by growth factor receptors and pathways like PI3K/Akt/mTOR, which are critical in tumor biology.
- **Adipocyte Differentiation**: Investigations into METAP2’s role in metabolism have identified potential implications in pathways governing adipocyte differentiation and function.

In summary, METAP2 encodes a critical enzyme influencing protein processing, cellular signaling, and potentially impacting cancer and metabolic disorders. Its relevance in aging and age-related diseases warrants further investigation.